Endocrine Abstracts

Background and aims: The most outstanding cardioprotective potential has been demonstrated for GLP-1 receptor agonists (GLP-1RA) and SGLT-2 inhibitors (SGLT-2i). But only long-acting GLP-1RA dulaglutide (DULA) and semaglutide decrease stroke incidence, while data concerning the influence of any drug on stroke severity are lack. At the same time, ischemic stroke remains one of the leading causes of death in type 2 diabetes mellitus (DM2). The aim of our study was to investigate...

Background and Aim: Type 2 diabetes mellitus (DM) treatment guidelines give preference to drugs with proven cardioprotective effect, which include sodium-glucose cotransporter type 2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA). GLP-1RA are known to reduce the stroke risk. Data on SGLT-2i effect on the brain, in conditions of both acute and chronic cerebrovascular disorders, are less complete. The aim of our study was to evaluate the effect of h...

Background and aimsAlthough bone fracture risk increases in DM, bone mineral density does not completely reflect bone fragility. It is important to explore other methods of osteoporotic fracture risk evaluation. Nowadays bone turnover markers (BTM) investigation is not widely used in clinical practice. On the other hand, the action of some glucose-lowering drugs on bone remodeling is not completely explored. The aim of this study was to investigate and t...

Background:Myocardial infarction (MI) is one of the leading causes of mortality in patients with type 2 diabetes mellitus (DM), therefore it is essential to give preference to a glucose-lowering drug having most prominent cardioprotective properties. Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) have demonstrated an ability to decrease heart failure manifestations, cardiovascular death frequency not having a certain influence on MI occurrence. On ...